United States
Invitrocue is an innovative life sciences company that specializes in developing ground-breaking 3D cell-based models such as Patient-Derived Organoids (PDOs) from all solid cancers. The company's Onco-PDO technology enables patient-derived cancer cells to be cultured in laboratories for testing against a panel of drugs to support personalized clinical decisions. By utilizing the Onco-PDO test, Invitrocue performs in vitro drug screenings on PDOs to provide oncologists with the information to better direct patient therapy and personalized treatment.
Founded in 2012, Invitrocue is headquartered in Singapore with operations in Australia, China, Hong Kong, and Germany. The company's goal is to create a healthier society by providing patients with the best possible care through the development of more effective and affordable disease treatments. Invitrocue operates within the biotechnology, healthcare, and manufacturing industries.
With a focus on transforming bioanalytics, Invitrocue contributes valuable knowledge to the industry in creating better, faster, and more affordable disease treatments. While the details on the last investment and investors are not available at the moment, the company's dedication to advancing personalized medicine and improving patient care is evident in its innovative approach.
For more information, please visit: https://www.invitrocue.com
